This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koong, S.-S. Articles by Robbins, J. Search for Related Content PubMed PubMed Citation Articles by Koong, S.-S. Articles by Robbins, J.

Lithium as a Potential Adjuvant to ¹³¹I Therapy of Metastatic, Well Differentiated Thyroid Carcinoma¹

Nuclear Medicine Department, Warren Grant Magnuson Clinical Center (S.-S.K., J.C.R., A.M.K.), and the Clinical Endocrinology (E.G.M., K.B.A., M.C.L., J.R.) and Genetics and Biochemistry Branchs, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: James C. Reynolds, M.D., Building 10, Room 1C-401, National Institutes of Health, Bethesda, Maryland 20892.

As lithium inhibits the release of iodine from the thyroid but does not change iodine uptake, it may potentiate ¹³¹I therapy of thyroid cancer. The effects of lithium on the accumulation and retention of ¹³¹I in metastatic lesions and thyroid remnants were evaluated in 15 patients with differentiated thyroid carcinoma. Two ¹³¹I turnover studies were performed while the patients were hypothyroid. One was performed while the patient received lithium; the second served as a control study. From a series of -camera images, it was found that lithium increased ¹³¹I retention in 24 of 31 metastatic lesions and in 6 of 7 thyroid remnants. A comparison of ¹³¹I retention during lithium with that during the control period showed that the mean increase in the biological or retention half-life was 50% in tumors and 90% in remnants. This increase occurred in at least 1 lesion in each patient and was proportionally greater in lesions with poor ¹³¹I retention. When the control biological half life was less than 3 days, lithium prolonged the effective half-life, which combines both biological turnover and isotope decay, in responding metastases by more than 50%. More ¹³¹I also accumulated during lithium therapy, probably as a consequence of its effect on iodine release. The increase in the accumulated ¹³¹I and the lengthening of the effective half-life combined to increase the estimated ¹³¹I radiation dose in metastatic tumor by 2.29 ± 0.58 (mean ± SEM) times. These studies suggest that lithium may be a useful adjuvant for ¹³¹I therapy of thyroid cancer, augmenting both the accumulation and retention of ¹³¹I in lesions.

This article has been cited by other articles:

				D. G. Pfister and J. A. Fagin Refractory Thyroid Cancer: A Paradigm Shift in Treatment Is Not Far Off J. Clin. Oncol., October 10, 2008; 26(29): 4701 - 4704. [Full Text] [PDF]

				F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF]

				R. Elisei, A. Vivaldi, R. Ciampi, P. Faviana, F. Basolo, F. Santini, C. Traino, F. Pacini, and A. Pinchera Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2389 - 2395. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri Empirically Treating High Serum Thyroglobulin Levels J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088. [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]

				U. Haberkorn, P. Beuter, W. Kubler, H. Eskerski, M. Eisenhut, R. Kinscherf, S. Zitzmann, L. G. Strauss, A. Dimitrakopoulou-Strauss, and A. Altmann Iodide Kinetics and Dosimetry In Vivo After Transfer of the Human Sodium Iodide Symporter Gene in Rat Thyroid Carcinoma Cells J. Nucl. Med., May 1, 2004; 45(5): 827 - 833. [Abstract] [Full Text] [PDF]

				D. A. Meier, D. R. Brill, D. V. Becker, S. E.M. Clarke, E. B. Silberstein, H. D. Royal, and H. R. Balon Procedure Guideline for Therapy of Thyroid Disease with 131Iodine J. Nucl. Med., June 1, 2002; 43(6): 856 - 861. [Full Text] [PDF]

				J. W. A. Smit, J. P. Schroder-van der Elst, M. Karperien, I. Que, M. Stokkel, D. van der Heide, and J. A. Romijn Iodide Kinetics and Experimental 131I Therapy in a Xenotransplanted Human Sodium-Iodide Symporter-Transfected Human Follicular Thyroid Carcinoma Cell Line J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1247 - 1253. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				Y. Nakamoto, T. Saga, T. Misaki, H. Kobayashi, N. Sato, T. Ishimori, S. Kosugi, H. Sakahara, and J. Konishi Establishment and Characterization of a Breast Cancer Cell Line Expressing Na+/I- Symporters for Radioiodide Concentrator Gene Therapy J. Nucl. Med., November 1, 2000; 41(11): 1898 - 1904. [Abstract] [Full Text] [PDF]